BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals LLC today announced the launch of its branded Esomeprazole Strontium 49.3 mg delayed-release capsules. Esomeprazole Strontium contains the same active moiety (esomeprazole) in a different salt form as found in the branded proton-pump inhibitor Nexium® (esomeprazole magnesium) and is a new option for adult patients for the short term treatment of gastroesophageal reflux disease (GERD). Amneal is marketing the 505(b)(2) product in the United States under an exclusive license and distribution agreement with Hanmi Pharmaceutical Co. Ltd of South Korea.
Help employers find you! Check out all the jobs and post your resume.
